钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者心血管保护作用的研究进展

doi:10.3969/j.issn.1674-8115.2021.03.019

摘要/Abstract

摘要：

钠-葡萄糖共转运蛋白2抑制剂（sodium-glucose cotransporter 2 inhibitor，SGLT2i）是一种新型降糖药，可降低2型糖尿病患者的全因死亡率，以及发生主要不良心脏事件和因心力衰竭而住院的风险。研究发现，除降糖作用外，SGLT2i还可通过降低心脏前后负荷、改善血流动力学、抗心肌纤维化、改变心脏能量供应等机制发挥心血管保护作用。该文对近年来有关SGLT2i的相关临床试验及机制进行综述，探讨SGLT2i对2型糖尿病患者的心血管保护作用。

关键词: 钠-葡萄糖共转运蛋白2抑制剂, 2型糖尿病, 心血管疾病, 恩格列净, 卡格列净, 达格列净

Abstract:

As a novel anti-diabetes drug, sodium-glucose cotransporter 2 inhibitor (SGLT2i) can decrease the all-cause mortality, the risk of major adverse cardiac event (MACE) and rate of heart failure hospitalization in patients with type 2 diabetes. Studies found that besides the function of glycemic control, SGLT2i could reduce the preload and afterload of heart, improve the hemodynamics, attenuate myocardial fibrosis and rejuvenate myocardial energetics. In this paper, clinical trials about SGLT2i in recent years and the mechanisms are reviewed to discuss the progress of the cardioprotection effect of SGLT2i on patients with type 2 diabetes.

Key words: sodium-glucose cotransporter 2 inhibitor, type 2 diabetes, cardiovascular disease, empagliflozin, canagliflozin, dapagliflozin

中图分类号:

R587.2

孙敏, 张冬颖. 钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者心血管保护作用的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(3): 391-395.

Min SUN, Dong-ying ZHANG. Progress of cardioprotection effect of sodium-glucose cotransporter 2 inhibitor on patients with type 2 diabetes[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 391-395.

参考文献 33

1	申珂, 郭娜娜, 邓健,等. 中国近 40 年慢性病疾病谱变化情况[J]. 山西医药杂志, 2017, 46(8): 903-905.
2	Galbete A, Cambra K, Forga L, et al. Achievement of cardiovascular risk factor targets according to sex and previous history of cardiovascular disease in type 2 diabetes: a population-based study[J]. J Diabetes Complicat, 2019, 33(12): 107445.
3	Association AD. Standards of medical care in diabetes: 2020 abridged for primary care providers[J]. Clin Diabetes, 2020, 38(1): 10-38.
4	Zhu JH, Yu XX, Zheng YY, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map[J]. Lancet Diabetes Endocrinol, 2020, 8(3): 192-205.
5	Douros A, Dell'Aniello S, Yu OHY, et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study[J]. BMJ, 2018, 362: k2693.
6	Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group[J]. Lancet, 1998, 352(9131): 837-853.
7	Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes[J]. N Engl J Med, 2008, 358(24): 2545-2559.
8	Schnell O, Standl E, Catrinoiu D, et al. Report from the 1st cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group[J]. Cardiovasc Diabetol, 2016, 15: 33.
9	Basile J. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition[J]. Postgrad Med, 2011, 123(4): 38-45.
10	Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects[J]. Nat Rev Endocrinol, 2012, 8(8): 495-502.
11	Han SP, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats[J]. Diabetes, 2008, 57(6): 1723-1729.
12	Pancholia AK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus[J]. Indian Heart J, 2018, 70(6): 915-921.
13	Powell J, Miller SA, Taylor JR. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management[J]. South Med J, 2015, 108(2): 82-90.
14	Allegretti AS, Zhang WB, Zhou WJ, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD[J]. Am J Kidney Dis, 2019, 74(3): 328-337.
15	Ku EJ, Lee DH, Jeon HJ, et al. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: a 52-week prospective observational study[J]. Diabetes Res Clin Pract, 2019, 151: 65-73.
16	高武通. 钠葡萄糖同向转运蛋白2抑制剂治疗2型糖尿病的研究新进展[J]. 浙江医学, 2018, 40(16): 1882-1885.
17	Matthews D, Fulcher G, Perkovic V, et al. Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D)[J]. Diabetol Und Stoffwechsel, 2013, 8(S01). DOI: 10.1055/s-0033-1341911.
18	Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128.
19	Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)[J]. Circulation, 2017, 136(3): 249-259.
20	Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7): 644-657.
21	Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study[J]. BMJ, 2018, 360: k119.
22	Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study[J]. J Am Coll Cardiol, 2018, 71(23): 2628-2639.
23	Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357.
24	McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008.
25	Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet, 2019, 393(10166): 31-39.
26	Ghezzi C, Yu AS, Hirayama BA, et al. Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule[J]. J Am Soc Nephrol, 2017, 28(3): 802-810.
27	Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure[J]. JAMA Cardiol, 2017, 2(9): 939-940.
28	Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis[J]. Diabetes Obes Metab, 2018, 20(3): 479-487.
29	Li CG, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J]. Cardiovasc Diabetol, 2019, 18(1): 15.
30	Fedak PW, Verma S, Weisel RD, et al. Cardiac remodeling and failure From molecules to man (Part II) [J]. Cardiovasc Pathol, 2005, 14(2): 49-60.
31	Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts[J]. Free Radic Biol Med, 2017, 104: 298-310.
32	Mizuno Y, Harada E, Nakagawa H, et al. The diabetic heart utilizes ketone bodies as an energy source[J]. Metab Clin Exp, 2017, 77: 65-72.
33	Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review[J]. Diabetologia, 2018, 61(10): 2108-2117.

[1]	张佳思, 邹春波, 卢宇, 陈茜, 张伟亚, 何姣姣. 血脂蛋白磷脂酶A2和中性粒细胞明胶酶相关脂质运载蛋白在诊断早期糖尿病肾病中的价值[J]. 上海交通大学学报(医学版), 2021, 41(6): 770-775.
[2]	蔡明琪, 陈焱, 林开斌, 黄冬. 生长分化因子11在心血管疾病中的作用[J]. 上海交通大学学报(医学版), 2021, 41(6): 834-838.
[3]	丁远森, 王枫, 孙家悦, 邵正威, 邹德荣, 陆家瑜. 不同年龄2型糖尿病患者牙周健康流行病学调查[J]. 上海交通大学学报(医学版), 2021, 41(2): 217-222.
[4]	代华杰, 禤立平, 项家丽, 林泓, 赵志云, 王天歌, 李勉, 徐瑜, 陆洁莉, 王卫庆, 毕宇芳, 徐敏. 上海市社区中老年人群健康的血管衰老和心血管疾病患病风险的相关性研究[J]. 上海交通大学学报(医学版), 2021, 41(2): 223-227.
[5]	陆言巧，沈兰，何奔. 人工智能在心血管疾病的辅助诊疗中的应用[J]. 上海交通大学学报（医学版）, 2020, 40(2): 259-.
[6]	王婷婷 1, 2，李明杰 1，林宁 1，钮忆欣 1，简蔚霞 1，苏青 1. 血清高尿酸水平与住院糖尿病患者白蛋白尿短期进展的关系研究[J]. 上海交通大学学报（医学版）, 2019, 39(7): 754-.
[7]	高玮 1，王雪姣 2，甄琴 2，丁晓颖 2，徐浣白 2，王育璠 2，彭永德 2. 2型糖尿病患者心率变异性降低的危险因素分析[J]. 上海交通大学学报（医学版）, 2019, 39(6): 629-.
[8]	王凌霄，刘婷婷，杨晓辉，姚智卿，蔡慧珍. 枸杞多糖对髓样分化因子 88基因敲除小鼠 2型糖尿病模型炎症因子的影响[J]. 上海交通大学学报（医学版）, 2019, 39(2): 136-.
[9]	陈丽，陈颖超，仰礼真. 2型糖尿病患者糖化血红蛋白与血黏度及外周动脉血流的相关性研究[J]. 上海交通大学学报（医学版）, 2019, 39(12): 1442-.
[10]	金志萍 1，张珊 2，于雪梅 2，陈海冰 3，胡承 3. 社区 2型糖尿病患者甲状腺结节危险因素研究分析[J]. 上海交通大学学报（医学版）, 2018, 38(9): 1066-.
[11]	朱凡凡，仰礼真. 甲状腺功能正常的2型糖尿病患者血清甲状腺激素水平与非酒精性脂肪性肝病的相关性[J]. 上海交通大学学报（医学版）, 2018, 38(7): 763-.
[12]	季海英，尤纱纱，曹惠敏，何斌. PCSK9 抑制剂降低低密度脂蛋白胆固醇的临床研究进展[J]. 上海交通大学学报（医学版）, 2018, 38(2): 212-.
[13]	赵丹丹,顾燕云,王计秋,胡春秀,洪洁,张翼飞,SPREAD-DIMCAD 研究组 . 基线脂代谢谱特征对降糖药物干预再发心血管事件影响的预测研究[J]. 上海交通大学学报（医学版）, 2017, 37(6): 744-.
[14]	闵丹燕，陆晓蓉，李振元，严豪，张敏芳，王琴，袁江姿，倪兆慧，方炜. 低T 3 综合征可预测腹膜透析患者的不良预后[J]. 上海交通大学学报（医学版）, 2017, 37(11): 1501-.
[15]	徐季超，胡皓璐，丁薇. 2型糖尿病老年患者血清维生素D水平与周围神经病变的关系[J]. 上海交通大学学报（医学版）, 2017, 37(05): 684-.